Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference
| Autor: | Christopher F. O'Brien, Martha Sajatovic, Andrew J. Cutler, Mark Stacy, Christoph U. Correll, John M. Kane, Grace S. Liang |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Movement disorders Tetrabenazine Minimal Clinically Important Difference MCID Tardive dyskinesia 03 medical and health sciences 0302 clinical medicine Humans Tardive Dyskinesia Medicine Valbenazine Research Articles Aged Mood Disorders business.industry Minimal clinically important difference AIMS clinical trial Valine Middle Aged medicine.disease Treatment Outcome 030104 developmental biology Psychotic Disorders Neurology Dyskinesia valbenazine Deutetrabenazine Vesicular Monoamine Transport Proteins Schizophrenia Clinical Global Impression Physical therapy Female sense organs Neurology (clinical) Abnormal Involuntary Movement Scale Erratum medicine.symptom business 030217 neurology & neurosurgery Research Article Antipsychotic Agents |
| Zdroj: | Mov Disord Movement Disorders |
| ISSN: | 1531-8257 0885-3185 |
| DOI: | 10.1002/mds.27769 |
| Popis: | Background A minimal clinically important difference has not been established for the Abnormal Involuntary Movement Scale in patients with tardive dyskinesia. Valbenazine is a vesicular monoamine transporter 2 inhibitor approved for the treatment of tardive dyskinesia in adults. Efficacy in randomized, double‐blind, placebo‐controlled trials was defined as the change from baseline in Abnormal Involuntary Movement Scale total score (sum of items 1‐7). Objectives To estimate an minimal clinically important difference for the Abnormal Involuntary Movement Scale using valbenazine trial data and an anchor‐based method. Methods Data were pooled from three 6‐week double‐blind, placebo‐controlled trials: KINECT (NCT01688037), KINECT 2 (NCT01733121), and KINECT 3 (NCT02274558). Valbenazine doses were pooled for analyses as follows: “low dose,” which includes 40 or 50 mg/day; and “high dose,” which includes 75 or 80 mg/day. Mean changes from baseline in Abnormal Involuntary Movement Scale total score were analyzed in all participants (valbenazine‐ and placebo‐treated) with a Clinical Global Impression of Change‐Tardive Dyskinesia or Patient Global Impression of Change score of 1 (very much improved) to 3 (minimally improved). Results The least squares mean improvement from baseline to week 6 in Abnormal Involuntary Movement Scale total score was significantly greater with valbenazine (low dose: –2.4; high dose: –3.2; both, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text